Bioengineered Protein Drugs Market Research Report Forecast to 2025

Majorly fuelling the global bioengineered protein drugs market is the rising occurrence of infectious diseases, diabetes, cancer, etc. This is because bioengineered protein drugs are more effective and additionally have reduced or no side effects when compared with alternative therapies for cancer, diabetes, and other maladies. This has led to more healthcare physicians prescribing these drugs, thereby stoking demand in the market.

The prospects in the global market for bioengineered protein drugs also looks upbeat owing to increasing drugs in phase III of clinical trials and many companies pouring money into research and development of novel bioengineered proteins.

Posing a roadblock to the market, on the other hand, is the steep cost of manufacturing bioengineered protein drug, having shorter shelf life. The emergence of biosimilars is also posing a severe challenge to the growth in the market.

A report by Transparency Market Research predicts the global bioengineered protein drugs market to expand at a 7.4% CAGR from 2017 to 2024 to become worth US$336.9 bn by 2025 from US$177.7 bn in 2016.

This report gives readers a comprehensive overview of the Bioengineered Protein Drugs Market:
http://www.transparencymarketresearch.com/bioengineered-proteins-drugs-market.html

The global bioengineered protein drugs market can be classified into monoclonal antibodies, vaccines, and therapeutic protein based upon the type of product. The therapeutic protein segment, among them, accounts for a dominant share because of extensive activities in the therapeutic protein engineering and recombinant DNA technology products. In terms of growth rate, however, the vaccines segment is expected to outshine all other segments by clocking maximum CAGR between 2017 to 2025 because of increase in development of bioengineered prophylactic and therapeutics vaccines.

From a geographical standpoint, North America leads the global bioengineered protein drugs market. In the years ahead, the region is slated is maintain its dominant position because of the rising occurrence of cancer and unveiling of innovative protein therapeutics for cancer. While loss of patents of blockbuster drugs such as Humira, Rituxan, Avastin, and Remicade, among others, are expected to deal a blow to the revenue in the market, launch of new drugs and approvals for new diagnostic tests, along with a growing geriatric population and unhealthy lifestyle will likely make up for it by inducing growth. As per the TMR report, the bioengineered protein drugs market in North America will likely register a CAGR of 7.2% from 2017 to 2025 to become worth US$161.05 bn by 2025.

Get accurate market forecast and analysis on the Bioengineered Protein Drugs Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8188

Though trailing North America, in terms of size, Europe is expected to lag behind all other regions vis-à-vis growth rate because of the patent loss of blockbuster drugs such as Humira, Avastin, and Lucentis and emergence of biosimilars.

Powered by India, China, and South Korea, Asia Pacific is expected to steal the show in the near future by expanding at a maximum CAGR of 9.0% from 2017 to 2025. Growing occurrence of cancer, massive investments by players, and rapid rise in healthcare infrastructure are said to be boosting growth in the region. China is at the forefront of driving growth in the region because of the sizeable proportion cancer patients, increasing geriatric population, launch of premium-priced targeted therapies, and rise in number of people covered under private health insurance in the country.

Some of the key players in the global bioengineered protein drugs market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Amgen, Inc., Bayer AG, Merck & Co., Inc., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Eli Lilly and Company, Sanofi, GlaxoSmithKline plc, Johnson & Johnson (JanssenNovartis AG, Panacea Biotec, and ProBioGen AG.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.